Abstract
Objective
To characterize late preterm antenatal steroids (AS) use and associated neonatal outcomes in a single academic center.
Study design
Retrospective study of 503 singleton, mother-infant dyads delivered between 34 0/7 and 36 6/7 weeks gestation between January 1, 2016 and December 31, 2020.
Results
Forty-three percent did not receive AS (No AS) prior to delivery. Among AS treated, 50% were sub-optimal dosing. No AS had higher preterm premature rupture of membranes and maternal diabetes. AS group had lower mean gestational age, birthweight, longer time from admission to delivery and longer NICU stay. There was no difference in neonatal hypoglycemia.
Conclusions
Sub-optimal AS dosing in late preterms remains high in our center. AS did not improve neonatal outcomes. Studies are needed to evaluate the impact of AS in diabetics delivering late preterm, to optimize the timing of AS dosing, and evaluate the longer term impact on late preterm infants.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Society for Maternal-Fetal Medicine. Electronic address pso, Reddy UM, Deshmukh U, Dude A, Harper L, Osmundson SS. Society for Maternal-Fetal Medicine Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late preterm delivery: Replaces SMFM Statement #4, Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery, August 2016. Am J Obstet Gynecol. 2021;225:B36–B42.
Committee on Obstetric P. Committee opinion no. 713: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2017;130:e102–e9.
Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita AT, Reddy UM, Saade GR, et al. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med. 2016;374:1311–20.
Uquillas KR, Lee RH, Sardesai S, Chen E, Ihenacho U, Cortessis VK, et al. Neonatal hypoglycemia after initiation of late preterm antenatal corticosteroids. J Perinatol. 2020;40:1339–48.
Kemp MW, Jobe AH, Usuda H, Nathanielsz PW, Li C, Kuo A, et al. Efficacy and safety of antenatal steroids. Am J Physiol Regul Integr Comp Physiol. 2018;315:R825–R39.
Deshmukh M, Patole S. Antenatal corticosteroids for impending late preterm (34-36+6 weeks) deliveries-A systematic review and meta-analysis of RCTs. PLoS One. 2021;16:e0248774.
Raikkonen K, Gissler M, Tapiainen T, Kajantie E. Associations between maternal antenatal corticosteroid treatment and psychological developmental and neurosensory disorders in children. JAMA Netw Open. 2022;5:e2228518.
Collaborators WAT. Antenatal dexamethasone for late preterm birth: a multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial. EClinicalMedicine. 2022;44:101285.
Battarbee AN, Clapp MA, Boggess KA, Kaimal A, Snead C, Schulkin J, et al. Practice variation in antenatal steroid administration for anticipated late preterm birth: a physician survey. Am J Perinatol. 2019;36:200–4.
McElwee ER, Wilkinson K, Crowe R, Newman JC, Alkis M, Wineland R, et al. Indication creep of antenatal late preterm steroids. Am J Perinatol. 2022;39:1159–65.
ACOG Practice Bulletin No. 190. Gestational diabetes mellitus. Obstet Gynecol. 2018;131:e49–e64.
McEvoy C, Bowling S, Williamson K, Stewart M, Durand M. Functional residual capacity and passive compliance measurements after antenatal steroid therapy in preterm infants. Pediatr Pulmonol. 2001;31:425–30.
McEvoy C, Bowling S, Williamson K, Collins J, Tolaymat L, Maher J. Timing of antenatal corticosteroids and neonatal pulmonary mechanics. Am J Obstet Gynecol. 2000;183:895–9.
McEvoy C, Bowling S, Williamson K, Lozano D, Tolaymat L, Izquierdo L, et al. The effect of a single remote course versus weekly courses of antenatal corticosteroids on functional residual capacity in preterm infants: a randomized trial. Pediatrics. 2002;110:280–4.
McEvoy C, Schilling D, Peters D, Tillotson C, Spitale P, Wallen L, et al. Respiratory compliance in preterm infants after a single rescue course of antenatal steroids: a randomized controlled trial. Am J Obstet Gynecol. 2010;202:544 e1–9.
Go M, Schilling D, Nguyen T, Durand M, McEvoy CT. Respiratory compliance in late preterm infants (34(0/7)-34(6/7) weeks) after antenatal steroid therapy. J Pediatr. 2018;201:21–6.
Brand PL, Molenaar NL, Kaaijk C, Wierenga WS. Neurodevelopmental outcome of hypoglycaemia in healthy, large for gestational age, term newborns. Arch Dis Child. 2005;90:78–81.
Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics. 2008;122:65–74.
Duvanel CB, Fawer CL, Cotting J, Hohlfeld P, Matthieu JM. Long-term effects of neonatal hypoglycemia on brain growth and psychomotor development in small-for-gestational-age preterm infants. J Pediatr. 1999;134:492–8.
Kerstjens JM, Bocca-Tjeertes IF, de Winter AF, Reijneveld SA, Bos AF. Neonatal morbidities and developmental delay in moderately preterm-born children. Pediatrics. 2012;130:e265–72.
Lucas A, Morley R, Cole TJ. Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia. BMJ. 1988;297:1304–8.
Tam EW, Haeusslein LA, Bonifacio SL, Glass HC, Rogers EE, Jeremy RJ, et al. Hypoglycemia is associated with increased risk for brain injury and adverse neurodevelopmental outcome in neonates at risk for encephalopathy. J Pediatr. 2012;161:88–93.
Tin W, Brunskill G, Kelly T, Fritz S. 15-year follow-up of recurrent “hypoglycemia” in preterm infants. Pediatrics. 2012;130:e1497–503.
Funding
This work was supported by 2 KL2 TR002370-06(MDG); NHLBI R01 HL105447 with co-funding from the Office of Dietary Supplements (ODS), NIH UH3OD023288 from the Environmental influences on Child Health Outcomes Program (ECHO), NIH R33HL147906 (CMT). Additional support from the Oregon Clinical Translational Research Institute funded by the National Center for Advancing Translational Sciences (UL1TR002369).
Author information
Authors and Affiliations
Contributions
MG and CM conceived and designed the study, contributed to data analysis and interpretation; MG wrote the manuscript with support from MW, TK, and CM. MW and TK collected data and performed the data analysis. All authors discussed the results and contributed to the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
The study was approved by the Oregon Health & Science University Institutional Review Board (IRB Study#22726) and was performed in accordance with the Declaration of Helsinki.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Go, M., Wahl, M., Kruss, T. et al. Late preterm antenatal steroid use and infant outcomes in a single center. J Perinatol (2024). https://doi.org/10.1038/s41372-024-01934-2
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41372-024-01934-2